Tarsus Pharmaceuticals, Inc.

TARS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$116-$136-$62-$14
Dep. & Amort.$1$1$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$28$20$13$8
Change in WC$4$0-$1$1
Other Non-Cash-$0-$3$0$7
Operating Cash Flow-$83-$117-$49$4
Investing Activities
PP&E Inv.-$2-$2-$1-$1
Net Acquisitions$0$0$144$0
Inv. Purchases-$266-$29-$149$0
Inv. Sales/Matur.$73$175$5$0
Other Inv. Act.-$5-$4-$144$0
Investing Cash Flow-$199$141-$145-$1
Financing Activities
Debt Repay.$40$10$19$0
Stock Issued$115$120$75$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$155$130$94$0
Forex Effect$0$0$0$0
Net Chg. in Cash-$128$153-$100$3
Supplemental Information
Beg. Cash$225$72$171$168
End Cash$97$225$72$171
Free Cash Flow-$85-$123-$50$3
Tarsus Pharmaceuticals, Inc. (TARS) Financial Statements & Key Stats | AlphaPilot